RAB7B

Across TCGA pan-cancer cohorts, RAB7B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RAB7B data layer compared with 21 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher RAB7B mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated RAB7B expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

LSCC, LUAD, and PDAC are the cancer types where RAB7B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	All	1.000	0.939	.013	14	view →
LUAD	DFS	Quartile	All	0.836	0.490	.012	9	view →
PDAC	OS	Median	II,III,IV	0.260	0.670	.006	8	view →
OV	DFS	Median	All	1.000	0.726	.036	4	view →
HNSC	OS	Median	III,IV	0.792	0.931	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RAB7B–LSCC (OS)

Open the LSCC breakdown →